Esther Jovell-Fernandez

Esther Jovell-Fernandez

Auto-generated profile, based on publicly available information

Esther Jovell-Fernandez

Department of Medicine, School of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC Barcelona), Campus Sant Cugat, Josep Trueta s/n, Sant Cugat del Vallès, 08195 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
JLJoan Lozano
Joan Lozano
CFCarlos G. Forero
Carlos G. Forero
MTMontserrat Colomer i Truyols
Montserrat Colomer i Truyols
SRSaturio Paredes Rubio
Saturio Paredes Rubio
EJEsther Jovell-Fernandez
Esther Jovell-Fernandez

7 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
FCFelipe Counago
Felipe Counago
SRSaturio Paredes Rubio
Saturio Paredes Rubio
MGManuel Galdeano-Rubio
Manuel Galdeano-Rubio
EJEsther Jovell-Fernandez
Esther Jovell-Fernandez
Background: Biochemical recurrence (BCR) after definitive radiotherapy (RT) in localized prostate cancer (PC) is a clinically relevant event that impacts long-term management and prognosis. However, the prognostic value of certain biopsy-derived pathological parameters remains underexplored in RT-treated cohorts. Methods: We retrospectively analyzed 444 patients with localized PC treated with external beam radiotherapy (with or without androgen deprivation therapy) between 2013 and 2019. Clinical, radiological, and detailed histopathological data, including Gleason score, perineural invasion, and the number and proportion of positive biopsy cores—were collected. Logistic regression models were used to identify predictors of BCR. Results: After a median follow-up of 72 months, 11.7% of patients developed BCR. In multivariable analysis, higher PSA at diagnosis (p = 0.05), higher Gleason score (ISUP ≥ 4; p = 0.036), and greater tumor burden in biopsy cores—quantified as both the number and proportion of positive cores per lobe and overall (p < 0.05)—were independently associated with BCR. Perineural invasion showed a univariable association (p = 0.036), though it did not remain significant after adjustment. Overall, 19.2% (10/52) of recurrences were diagnosed beyond five years post-treatment, underscoring the need for prolonged follow-up. Conclusions: PSA at diagnosis, the extent of tumor involvement in diagnostic biopsies, and ISUP grade group ≥ 4 (Gleason score ≥ 8) were identified as independent predictors of biochemical recurrence after RT in localized prostate cancer. Lower Gleason categories and perineural invasion showed only a trend toward significance in the multivariable analysis, suggesting that their predictive effect may be attenuated by other covariates.

1 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
FCFelipe Counago
Felipe Counago
SRSaturio Paredes Rubio
Saturio Paredes Rubio
MGManuel Galdeano-Rubio
Manuel Galdeano-Rubio
EJEsther Jovell-Fernandez
Esther Jovell-Fernandez
Prognostic Factors Associated with Biochemical Relapse after Radiotherapy in Localized Prostate Cancer: A Retrospective Cohort Study Background: Biochemical recurrence (BCR) after definitive radiotherapy (RT) in localized prostate cancer (PC) is a clinically relevant event that impacts long-term management and prognosis. However, the prognostic value of certain biopsy-derived pathological parameters remains underexplored in RT-treated cohorts. Methods: We retrospectively analyzed 444 patients with localized PC treated with external beam radiotherapy (with or without androgen deprivation therapy) between 2013 and 2019. Clinical, radiological, and detailed histopathological data, including Gleason score, perineural invasion, and the number and proportion of positive biopsy cores—were collected. Logistic regression models were used to identify predictors of BCR. Results: After a median follow-up of 72 months, 11.7% of patients developed BCR. In multivariable analysis, higher PSA at diagnosis (p = 0.05), higher Gleason score (ISUP ≥4; p = 0.036), and greater tumor burden in biopsy cores—quantified as both number and proportion of positive cores per lobe and overall (p < 0.05)—were independently associated with BCR. Perineural invasion showed a univariable association (p = 0.036), though it did not remain significant after adjustment. Notably, nearly one-fourth of recurrences occurred beyond five years post-treatment, underscoring the need for prolonged follow-up. Conclusions: PSA level, Gleason grade, and extent of tumor involvement in diagnostic biopsies are strong, independent predictors of BCR following RT. These findings support the incorporation of detailed biopsy metrics into routine risk stratification to inform personalized surveillance strategies.